Horizon Pharma (HZNP) Tops Q2 EPS by 11c

Horizon Pharma (NASDAQ: HZNP) reported Q2 EPS of $0.21, $0.11 better than the analyst estimate of $0.10. Revenue for the quarter came in at $66.1 million versus the consensus estimate of $58.35 million.

For earnings history and earnings-related data on Horizon Pharma (HZNP) click here.

You May Also Be Interested In

• JPMorgan Upgrades Aviva Plc (AV/:LN) (AIVAF) to Overweight
• Cantor Fitzgerald Downgrades Monopar Therapeutics (MNPR) to Neutral
• Birkenstock Holding (BIRK) Misses Q3 EPS by 2c; lifts guidance